Skip to main content
GENFIT logo

GENFIT — Investor Relations & Filings

Ticker · GNFT ISIN · FR0004163111 LEI · 969500XPWN2DMZQA5X73 PA Professional, scientific and technical activities
Open in API
Filings indexed 681 across all filing types
Latest filing 2014-05-05 Investor Presentation
Country FR France
Listing PA GNFT

About GENFIT

https://www.genfit.com

GENFIT is a biopharmaceutical company dedicated to developing therapeutic and diagnostic solutions for patients with rare and severe liver diseases characterized by high unmet medical needs. The company's primary focus is on Acute-on-Chronic Liver Failure (ACLF) and its associated conditions, such as acute decompensation (AD) and hepatic encephalopathy (HE). Leveraging a scientific heritage of over two decades, GENFIT is a pioneer in liver disease research and development, aiming to improve the lives of patients with these life-threatening conditions.

Recent filings

Filing Released Lang Actions
2014.05.05 CP GENFIT Brevets NASH
Investor Presentation Classification · 95% confidence The document is explicitly titled "Communiqué de presse" (Press Release) and announces a major development regarding intellectual property (patent grant for GFT505 in NASH) and provides a brief overview of the company's status and future outlook. This format strongly suggests an immediate public announcement rather than a comprehensive periodic report (like 10-K or IR) or a formal regulatory filing like a proxy statement or earnings release. Since the core content is a press release announcing a specific corporate event (IP/Patent news), and there is no specific category for 'Press Release' or 'Corporate Announcement' that isn't already covered, I must evaluate the closest fit. It is not an Earnings Release (ER), nor a Capital/Financing Update (CAP), nor a Legal Report (LTR). Given the focus on intellectual property and drug development milestones, it is a general corporate update. The closest fit among the provided options that captures a significant, non-financial periodic announcement is often categorized under general Regulatory Filings (RNS) if a more specific category doesn't exist. However, since the content is a direct announcement of a business milestone (patent grant), and it is not a standard financial report, it falls best under the general regulatory/corporate announcement category, which is RNS, or potentially IP if that were an option. Given the choices, RNS serves as the best general regulatory/corporate announcement fallback for non-standard filings like this press release about IP.
2014-05-05 French
Transfert sur le marché réglementé d’Euronext à Paris – Compartiment B – Le 17 avril 2014
Delisting Announcement Classification · 99% confidence The document announces the transfer of GENFIT's stock listing from Alternext to the regulated market of Euronext Paris (Compartment B), effective April 17, 2014. It explicitly mentions the AMF (Autorité des marchés financiers) visa for the Prospectus issued for this direct listing. The core subject is a change in the company's capital structure/listing venue, which aligns with the 'Capital/Financing Update' (CAP) definition. Although a Prospectus is mentioned, the document itself is an announcement about the listing change and the associated regulatory approval (visa), rather than the full financing terms (CAP) or just a general regulatory filing (RNS). Given the focus on the listing transfer and the associated regulatory steps, CAP is the most specific fit, as it relates directly to capital structure changes and fundraising facilitation. It is not a general regulatory filing (RNS) because it concerns a specific capital market event.
2014-04-15 French
Transfer to the Euronext Paris regulated market – Compartment B – On April 17, 2014
Share Issue/Capital Change Classification · 95% confidence The document is a press release announcing the transfer of GENFIT's listing from the Alternext market to the Euronext Paris regulated market (Compartment B). It explicitly mentions obtaining a visa from the AMF for a Prospectus related to this listing. This action involves a significant change in the company's capital structure and listing status, which is related to financing and capital activities. While it mentions a Prospectus, the core announcement is about the listing transfer itself. This fits best under 'Capital/Financing Update' (CAP) as it details a change in the trading venue and market tier, which is a capital structure event, rather than a general regulatory filing (RNS) or a delisting announcement (DLST), as it is simultaneously moving to a higher regulated market. The document is short and acts as an announcement, but the subject matter is highly specific to capital structure change.
2014-04-15 English
Potentiel thérapeutique du GFT505 élargi à des pathologies fibrotiques non hépatiques ; Nouvel éclairage sur le mécanisme d'action anti-fibrotique
Regulatory Filings Classification · 95% confidence The document is a press release dated April 14, 2014, from the biopharmaceutical company GENFIT, announcing new data regarding the therapeutic potential of its drug candidate GFT505, specifically highlighting its anti-fibrotic properties in non-hepatic conditions like Crohn's disease. It details scientific findings presented at a conference (EASL 2014) and includes quotes from management about future plans (Phase 2 study in Crohn's). This content structure—announcing scientific progress, clinical pipeline updates, and strategic direction via a formal press release—is characteristic of an Investor Presentation (IP) or a general announcement. Since it is a detailed update on strategy and pipeline progress presented to investors/the public, Investor Presentation (IP) is the most fitting category, as it goes beyond a simple Earnings Release (ER) or a brief Fund Factsheet (FS). It is not a formal regulatory filing like a 10-K or an IR.
2014-04-14 French
Therapeutic potential of GFT505 widened to non-hepatic fibrotic diseases; New Insights on its anti-fibrotic mechanism of action
Regulatory Filings Classification · 95% confidence The document is a press release dated April 14, 2014, announcing new data regarding the therapeutic potential of the drug candidate GFT505, specifically focusing on its anti-fibrotic properties presented at an EASL congress. It details scientific findings and strategic considerations (potential Phase 2 study in Crohn's disease). This type of announcement, which communicates key business/scientific updates outside of mandatory periodic financial filings (like 10-K or IR), typically falls under general Investor Relations communication. Since it is not a full transcript (CT), a formal earnings release (ER), or a presentation deck (IP), and it is announcing scientific progress rather than a specific corporate action like a dividend (DIV) or share transaction (POS), it is best classified as a general Investor Relations document. Given the options, 'Regulatory Filings' (RNS) serves as the best general category for non-standard, non-financial press releases that update investors on operational/scientific progress, although 'IP' might be considered if it were explicitly a presentation deck. Since it reads like a news update about data presented, RNS is the most appropriate fallback for significant, non-standard investor news.
2014-04-14 English
Organisation d’un Workshop au Congrès Annuel de l’EASL autour du GFT505
Regulatory Filings Classification · 95% confidence The document is a press release from GENFIT announcing the organization of a 'workshop' at the EASL annual congress to present new data on their drug candidate GFT505 for NASH treatment. It details the speakers and the content to be presented. This type of announcement, which publicizes an upcoming event or presentation where new information will be shared, is best classified as an Investor Presentation (IP) if it were the presentation itself, or a general announcement. Since it is an announcement about an event where data will be unveiled, and it is not a formal regulatory filing like 10-K, ER, or IR, it fits best under a category related to investor communication or general news. Given the options, it is an announcement about sharing scientific/clinical data with investors/analysts, which aligns closely with the purpose of an Investor Presentation (IP) or a general Regulatory Filing (RNS). However, because it is a specific announcement about a scientific presentation rather than a formal financial report or a general regulatory notice, and it is short (3167 chars), it is most likely a specific corporate communication. Since it details upcoming data presentation, it is not a formal ER or IR. It is not a DEF 14A (Remuneration) or DIRS (Director's Dealing). It is a specific corporate update. Given the options, and recognizing it as a specific corporate communication about data presentation, 'RNS' (Regulatory Filings - general fallback) is a possibility, but 'IP' (Investor Presentation) often covers materials related to investor events. Since this is an *announcement* of a workshop, not the presentation itself, 'RPA' (Report Publication Announcement) is plausible if we consider the workshop material as the 'report'. However, the content is focused on scientific updates for an investor audience. I will lean towards 'RNS' as the most appropriate general category for non-standard corporate news releases that don't fit the specific financial report codes, as it is an announcement about a scientific event, not a formal financial report or a proxy statement.
2014-04-08 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.